Drug Information For: reEssence Vasodilator Formula
Ingredient Name: MINOXIDIL (mi-NOX-i-dill)
FOR EXTERNAL USE ONLY
reEssence Vasodilator Formula contains Minoxidil 2% at a concentration of 20 mg minoxidil per mL in a solu-
tion composed of alcohol, propylene glycol and water.
Minoxidil, a peripheral vasodilator, occurs as a white or off-white, odourless, crystalline solid which is readily
soluble in propylene glycol or ethanol, soluble in water to the extent of 2 mg/mL and is almost insoluble in
acetone, chloroform or ethyl acetate. The chemical name for minoxidil is 2, 4-diamino-6-piperidino-pyrimi-
Minoxidil topical solution showed no systemic effects related to absorption when tested in controlled clini-
cal trials in both normotensive and untreated hypertensive patients. Minoxidil does not interfere with vaso-
motor reflexes and therefore does not produce orthostatic hypotension. In experimental animals, the drug
does not enter the central nervous system (CNS) in significant amounts.
Following topical application, minoxidil is poorly absorbed from normal intact skin, with an average of ap-
proximately 1.7% of the total applied dose ultimately reaching the systemic circulation. In contrast, minoxidil
is almost completely absorbed from the gastrointestinal tract following oral administration of minoxidil tab-
lets. Following cessation of topical dosing of reEssence Vasodilator Formula approximately 95% of systemi-
cally absorbed minoxidil is eliminated within 4 days. The effects of concomitant dermal diseases on absorp-
The metabolic biotransformation of minoxidil absorbed following topical application has not been fully
determined. The active form of the drug appears to be a sulfated metabolite, minoxidil sulfate. Orally admin-
istered minoxidil is metabolised predominantly by conjugation with glucuronic acid at the N-oxide position
in the pyrimidine ring but also by conversion to more polar products. Minoxidil does not bind to plasma pro-
teins and its renal clearance corresponds to the glomerular filtration rate. Minoxidil does not cross the blood
brain barrier. Minoxidil and its metabolites are haemodialysable, and are excreted principally in the urine.
Topical minoxidil is contraindicated in patients with a history of hypersensitivity to minoxidil, propylene
Warnings and Precautions
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
Before starting on reEssence Vasodilator Formula the patient should have a healthy, normal scalp.
Although extensive use of topical minoxidil has not revealed evidence that enough minoxidil is absorbed
to have systemic effects, greater absorption because of misuse or individual variability or unusual sensitivity
could lead, at least theoretically, to a systemic effect, and patients need to be aware of this.
Accidental ingestion of reEssence Vasodilator Formula could lead to serious adverse effects. The following
adverse effects may be observed as a result of systemic absorption:
-increased frequency of angina or new onset of angina, or
-the potentiation of the orthostatic hypotension produced by guanethidine.
Patients with known cardiovascular disease or cardiac arrhythmias should contact a physician before using
reEssence Vasodilator Formula. reEssence Vasodilator Formula is recommended for use only in healthy adults
with normal cardiovascular status. The safety is unknown in patients with cerebrovascular disease, ischaemic
heart disease, cardiac arrhythmias or congestive heart failure. Patients with a history of underlying heart
disease should be aware that adverse effects in them might be especially serious. The consumer should stop
using the product and see a doctor if hypotension is detected or if experiencing chest pain, rapid heart beat,
faintness or dizziness, sudden unexplained weight gain, swollen hands or feet or persistent redness or irrita-
Patients treated with reEssence Vasodilator Formula should be monitored after starting therapy and periodi-
cally thereafter. If systemic effects should occur, discontinue use of reEssence Vasodilator Formula. If neces-
sary, fluid retention and oedema can be managed with diuretic treatment. Tachycardia and angina can be
controlled by administration of beta-adrenergic blocking drugs or other sympathetic nervous system sup-
reEssence Vasodilator Formula contains an alcohol base which will cause burning and irritation of the eye.
In the event of accidental contact with sensitive surfaces (eye, abraded skin, mucous membranes), the area
should be bathed with copious amounts of cool tap water. Inhalation of the spray mist should be avoided.
The effects of reEssence Vasodilator Formula in patients with concomitant skin diseases, or in those using
topical corticosteroids or other dermatological preparations, are unknown. There is a possibility that an
increase in bioavailability, of topically administered minoxidil, may occur in the presence of inflammatory
conditions of the scalp and such situations are to be avoided.
If a patient wishes to wear any form of protective headgear, he should be instructed to allow 1 hour to
elapse after using reEssence Vasodilator Formula before covering the head.
Some patients have experienced changes in hair colour and/or texture with reEssence Vasodilator Formula.
Carcinogenicity, Mutagenicity and Impairment of Fertility
Carcinogenic activity of minoxidil has been investigated following dietary administration to mice at 10-64
mg/kg/day, and following topical administration to mice and rats at 8-80 mg/kg/day. Minoxidil treatment
was associated with the development of benign pituitary tumours and malignant mammary tumours in
female mice, hepatic adenomas and splenic haemangiosarcomas in male mice, and adrenal medullary and
clitoral gland adenomas in female rats. The hepatic tumours were only observed at high dose levels. The
development of mammary adenocarcinomas in mice may be related to stimulation of prolactin release.
Tumour development in the pituitary, preputial and clitoral glands may also involve endocrine mechanisms,
while the vascular wall tumours in mouse spleen and adrenal medullary tumours in rats may be related to
the vasodilator activity of the drug.
In a 12-month photocarcinogenicity study in hairless mice, topical minoxidil did not accelerate the develop-
ment of dermal tumours initiated by ultraviolet light.
Genetic toxicology studies showed that minoxidil does not cause gene mutation in bacterial cells, but gene
mutation studies in mammalian cells have not been reported. Minoxidil had weak clastogenic activity in
a cytogenetics assay in Chinese hamster lung cells in vitro, but there was no evidence of similar effects in
cultured human lymphocytes, or in an in vivo assay (micronucleus test in mice). Minoxidil did not cause DNA
damage in an alkaline elution assay in Chinese hamster fibroblasts or unscheduled DNA synthesis in rat
In fertility studies in rats, minoxidil decreased live litter size at oral doses of 3-10 mg/kg/day and at 80 mg/
Use in Lactation
Systemically-absorbed minoxidil is secreted in human milk. reEssence Vasodilator Formula should not be
Subcutaneous administration of minoxidil at 80 mg/kg/day to lactating rats suppressed postnatal growth
and increased postnatal mortality of the offspring. These effects may have been due to interference with
nursing behaviour rather than to ingestion of drug-related material by the offspring.
Use in Children
Safety and efficacy of reEssence Vasodilator Formula in patients under 20 years of age have not been estab-
Use in Elderly
Safety and efficacy of reEssence Vasodilator Formula in patients over 80 years of age have not been estab-
In general reEssence Vasodilator Formula is well tolerated.
Most frequently reported adverse reactions with 2% topical minoxidil in commercial marketing experience
are dermatological reactions and include: local erythema, itching, and dry skin/scalp flaking, skin irritation,
rash, and dermatitis. Increased hair shedding can occur due to minoxidil's action of shifting hairs in the
resting telogen phase to the growing anagen phase (old hairs fall out as new hairs grow in their place). This
temporary increase in shedding generally occurs two to six weeks after beginning treatment and subsides
within a couple of weeks (first sign of action of minoxidil).
Rare cases of hypotension have been reported.
Rare cases of hypertrichosis (unwanted non-scalp hair including facial hair growth in women) upon initiation
of therapy with reEssence Vasodilator Formula have been reported.
There are currently no known drug interactions associated with the use of reEssence Vasodilator Formula.
Although it has not been clinically demonstrated, there exists the theoretical possibility of absorbed minoxi-
dil potentiating orthostatic hypotension in patients currently taking peripheral vasodilators.
Drugs for cutaneous use, e.g., tretinoin and anthralin/dithranol, which alter the stratum corneum barrier,
could result in increased absorption of cutaneously used minoxidil if applied concurrently.
Dosage and Administration.
FOR EXTERNAL USE ONLY.
Use reEssence Vasodilator Formula only as directed. Do not apply reEssence Vasodilator Formula to any area
A total dose of 1 mL reEssence Vasodilator Formula should be applied twice per day to the frontal and tem-
ple hairline scalp. The total daily dose should not exceed 2 mL. After applying reEssence Vasodilator Formula,
Apply reEssence Vasodilator Formula when the hair and scalp are thoroughly dry. Do not use a hairdryer to
speed the drying of reEssence Vasodilator Formula, because blowing air on the frontal hairline scalp may
decrease the effectiveness of reEssence Vasodilator Formula. reEssence Vasodilator Formula must remain in
contact with the frontal hairline scalp for several hours (up to 4 hours).
At least two to four months of twice daily applications of reEssence Vasodilator Formula are generally re-
quired before evidence of wrinkle reduction can be expected. Onset and degree may be variable among
Note: Following discontinuation of medication, relapse to pretreatment appearance has been reported to
reEssence Vasodilator Formula must only be used for application to the frontal and temple hairline scalp.
Avoid contact with eyes, nose, mouth and broken skin. reEssence Vasodilator Formula must not be taken by
reEssence Vasodilator Formula should be applied to a dry scalp and the solution allowed to dry naturally.
reEssence Vasodilator Formula should not be used 24 hours before or after hair treatments such as color or
perm. Sunscreens should be applied at least two hours after the application of reEssence Vasodilator Formu-
la, and shampooed off before the next application. Hats must not be worn for at least an hour after applying.
Patients should stop using reEssence Vasodilator Formula and seek immediate medical attention if experi-
encing any or the following: rapid heart rate, rapid weight gain, swelling or fluid retention, dizziness, chest or
Health Benefits of Tennis Babette M Pluim (1), J Bart Staal (2), Bonita L Marks (3), Stuart Miller (4), Dave Miley (4) (1) Royal Netherlands Lawn Tennis Association (KNLTB), Amersfoort, The Netherlands (2) Department of Epidemiology and Caphri Research Institute, Maastricht University, Maastricht, The (3) Department of Exercise and Sport Science, University of North Carolina at Chap
Notarzt (SGNOR) Begleittext zum Fähigkeitsprogramm Notarzt (SGNOR) Alle vital gefährdeten Patienten sollen ab Notfallort von speziell weitergebilde- ten, besonders ausgerüsteten und in ein Alarmsystem eingebundenen Ärzten und Ärztinnen zusammen mit Rettungssanitätern versorgt werden. Das Fä- higkeitsprogramm Notarzt SGNOR regelt diese Weiterbildung. Es wurde neu überarbeitet, u